🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Expedition to the Valley of Tears: a journey of resilience and connection. 44 patients and 8 oncologists crossed the Andes, side by side. “The journey is easier when we walk it together”

It’s encouraging to see experts from across the globe coming together to discuss the complexity of access to cancer care—and working together to build real, shared solutions.

UHN's 'Canada Leads' strategy aims to attract 100 early-career researchers to drive medical innovation and economic growth. Learn how UHN is shaping the future of healthcare 👇 bit.ly/44cB5Rt

Importante para el programa de mentoreo de Asociación Argentina de Oncología Clínica (AAOC) #AAOCJoven Pablo Mando Dana Narvaez, MD How To Write a Response to Reviewers - European Urology europeanurology.com/article/S0302-…

Grateful to be part of this global journey in oncology at #ASCO25 🌍 Honored to witness the impact of the IDEA program as it builds bridges, creates mentorships, and shapes a brighter future for cancer care around the world 🌟 #IDEA2025 Conquer Cancer, the ASCO Foundation

I totally agree!

So glad to finally meet my IDEA mentor, Stephanie Graff, MD, FACP, FASCO , in person! Her leadership and kindness are truly inspiring ✨ Grateful for the opportunity to build stronger international connections through mentorship and shared purpose. 🌍

It is my greatest honor to be paired with Dr. Dana Narvaez, MD 🇦🇷 as an #ASCO25 2025 International Development & Education Award Mentor. Looking forward to her visit to The Warren Alpert Medical School, her roundtable on global health with Boris Martinez and so much more!

At the ASCO Presidential Reception with Dr. Eric Small, elected President of ASCO. A great opportunity to talk about how building bridges across borders can drive global impact in cancer care. #ASCO25 #GlobalOncology #Leadership #Collaboration

📍ASCO25 – Day 3 Powerful presentation by Dr Turner on the long-awaited SERENA-6 trial. Dr Angie DeMichele, MD, MSCE, FASCO delivered a super interesting analysis of its clinical utility Is ctDNA redefining the landscape of breast cancer care? Exciting times ahead for precision oncology 👏

Happening Now! #ASCO25 Poster Session 👉 Use of baseline plasma circulating tumor DNA (#ctDNA) to predict duration of endocrine therapy and CDK4/6 inhibitor therapy and to analyze intrinsic vs acquired #EndocrineResistance. Pietro De Placido 📍Abs 1075 | Poster Bd 54 | Jun 2,

#ASCO25 Dr. Mukhtar presented I-SPY2 data showing ctDNA as a potential predictor of nodal burden after neoadjuvant therapy. Promising steps toward more personalized, biology-driven treatment decisions.

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) shorturl.at/ZnMI5

Today at Brown, we had the honor of listening to Dr. Stephanie Graff, MD, FACP, FASCO powerful talk on influential leadership. I deeply admire her ability to lead with both scientific excellence and profound human connection Conquer Cancer, the ASCO Foundation Legorreta Cancer Center at Brown University

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 🔗nejm.org/doi/full/10.10… 👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1) OncoAlert #OncoAlertAF #BreastCancer #RadOnc

A few quick 📸 of the ASCO Conquer Cancer, the ASCO Foundation #IDEA Grantees over their visit Legorreta Cancer Center at Brown University The Warren Alpert Medical School Brown University Health #globaloncology

It’s hard to believe it’s been 20 years since Steve told Stanford graduates to stay hungry and stay foolish. His powerful advice still rings true, and I hope it helps guide this year’s new grads as they begin their journey to become tomorrow’s leaders. stevejobsarchive.com/exhibits/stay-…